Tetra Therapeutics is clinical stage biotechnology company developing medicines for Alzheimer's Disease, Fragile X syndrome, Traumatic Brain Injury, major depression and schizophrenia. The drugs in our pipeline offer a new mechanism focused on PDE4B and PDE4D. Tetra designs drugs to treat memory loss and cognitive impairment by improving how the brain processes and stores information. Tetra's promising drug for Alzheimer's Disease, BPN-14770, is being developed in partnership with the NIH Blueprint Therapeutics program. Our PDE4B platform addresses neuroinflammation, progressive multiple sclerosis (MS), and chronic traumatic encephalopathy (CTE).